These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 9150822)

  • 1. Dose escalation vs. continued doses of paroxetine and maprotiline: a prospective study in depressed out-patients with inadequate treatment response.
    Benkert O; Szegedi A; Wetzel H; Staab HJ; Meister W; Philipp M
    Acta Psychiatr Scand; 1997 Apr; 95(4):288-96. PubMed ID: 9150822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A double-blind study comparing paroxetine and maprotiline in depressed outpatients.
    Szegedi A; Wetzel H; Angersbach D; Dunbar GC; Schwarze H; Philipp M; Benkert O
    Pharmacopsychiatry; 1997 May; 30(3):97-105. PubMed ID: 9211571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response to treatment in minor and major depression: results of a double-blind comparative study with paroxetine and maprotiline.
    Szegedi A; Wetzel H; Angersbach D; Philipp M; Benkert O
    J Affect Disord; 1997 Sep; 45(3):167-78. PubMed ID: 9298430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relapse prevention by means of paroxetine in ECT-treated patients with major depression: a comparison with imipramine and placebo in medium-term continuation therapy.
    Lauritzen L; Odgaard K; Clemmesen L; Lunde M; Ohrström J; Black C; Bech P
    Acta Psychiatr Scand; 1996 Oct; 94(4):241-51. PubMed ID: 8911559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A double-blind, multicentre study of paroxetine and maprotiline in major depression.
    Schnyder U; Koller-Leiser A
    Can J Psychiatry; 1996 May; 41(4):239-44. PubMed ID: 8726790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
    Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
    Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence why paroxetine dose escalation is not effective in major depressive disorder: a randomized controlled trial with assessment of serotonin transporter occupancy.
    Ruhé HG; Booij J; v Weert HC; Reitsma JB; Franssen EJ; Michel MC; Schene AH
    Neuropsychopharmacology; 2009 Mar; 34(4):999-1010. PubMed ID: 18830236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low doses of controlled-release paroxetine in the treatment of late-life depression: a randomized, placebo-controlled trial.
    Rapaport MH; Lydiard RB; Pitts CD; Schaefer D; Bartolic EI; Iyengar M; Carfagno M; Lipschitz A
    J Clin Psychiatry; 2009 Jan; 70(1):46-57. PubMed ID: 19026248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential benefits of slow titration of paroxetine treatment in an elderly population: eight-week results from a naturalistic setting.
    Gibiino S; Mori E; De Ronchi D; Serretti A
    J Clin Psychopharmacol; 2013 Aug; 33(4):565-9. PubMed ID: 23764690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, double-blind, 24-week study comparing the efficacy and tolerability of mirtazapine and paroxetine in depressed patients in primary care.
    Wade A; Crawford GM; Angus M; Wilson R; Hamilton L
    Int Clin Psychopharmacol; 2003 May; 18(3):133-41. PubMed ID: 12702891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brofaromine versus lithium addition to maprotiline. A double-blind study in maprotiline refractory depressed outpatients.
    Hoencamp E; Haffmans PM; Dijken WA; Hoogduin CA; Nolen WA; van Dyck R
    J Affect Disord; 1994 Mar; 30(3):219-27. PubMed ID: 8006248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Maprotiline versus fluvoxamine: comparison of their effects on the hypothalamo-hypophyseal-thyroid axis].
    De Mendonça Lima CA; Vandel S; Bonin B; Bechtel P; Carron R
    Encephale; 1997; 23(1):48-55. PubMed ID: 9172968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Hypericum extract WS 5570 and paroxetine in ongoing treatment after recovery from an episode of moderate to severe depression: results from a randomized multicenter study.
    Anghelescu IG; Kohnen R; Szegedi A; Klement S; Kieser M
    Pharmacopsychiatry; 2006 Nov; 39(6):213-9. PubMed ID: 17124643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder.
    Pollack MH; Lepola U; Koponen H; Simon NM; Worthington JJ; Emilien G; Tzanis E; Salinas E; Whitaker T; Gao B
    Depress Anxiety; 2007; 24(1):1-14. PubMed ID: 16894619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paroxetine and amitriptyline in the treatment of depression in general practice.
    Christiansen PE; Behnke K; Black CH; Ohrström JK; Bork-Rasmussen H; Nilsson J
    Acta Psychiatr Scand; 1996 Mar; 93(3):158-63. PubMed ID: 8739658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multicenter double-blind trial of paroxetine versus amitriptyline in depressed inpatients.
    Stuppaeck CH; Geretsegger C; Whitworth AB; Schubert H; Platz T; König P; Hinterhuber H; Fleischhacker WW
    J Clin Psychopharmacol; 1994 Aug; 14(4):241-6. PubMed ID: 7962679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid cycling triggered by pindolol augmentation of paroxetine, but not with desipramine.
    Kraus RP
    Depression; 1996; 4(2):92-4. PubMed ID: 9160648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose Escalation of Antidepressants in Unipolar Depression: A Meta-Analysis of Double-Blind, Randomized Controlled Trials.
    Dold M; Bartova L; Rupprecht R; Kasper S
    Psychother Psychosom; 2017; 86(5):283-291. PubMed ID: 28903107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A double-blind study of paroxetine compared with fluoxetine in geriatric patients with major depression.
    Schöne W; Ludwig M
    J Clin Psychopharmacol; 1993 Dec; 13(6 Suppl 2):34S-39S. PubMed ID: 8106654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and tolerability of mirtazapine in treating major depressive disorder with anxiety symptoms: an 8-week open-label randomised paroxetine-controlled trial.
    Kim JE; Yoon SJ; Kim J; Jung JY; Jeong HS; Cho HB; Shin E; Lyoo IK; Kim TS
    Int J Clin Pract; 2011 Mar; 65(3):323-9. PubMed ID: 21314870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.